Cargando…
The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis
SUMMARY: Oral glucocorticoids may increase major osteoporotic fracture risk (MOF) in myasthenia gravis patients. To assess this risk, we performed a case–control study including all Danish patients with a MOF between 1995 and 2011. We also pooled our data with data from another study. We found no in...
Autores principales: | Safipour, Zohreh, van der Zanden, Rogier, van den Bergh, Joop, Janssen, Paddy, Vestergaard, Peter, de Vries, Frank, Driessen, Johanna H. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843904/ https://www.ncbi.nlm.nih.gov/pubmed/34601629 http://dx.doi.org/10.1007/s00198-021-06101-3 |
Ejemplares similares
-
Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis
por: Oshagbemi, O. A., et al.
Publicado: (2017) -
Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2019) -
RETRACTED ARTICLE: Secular trends in major osteoporotic fractures among 50+ adults in Denmark between 1995 and 2010
por: Abtahi, Shahab, et al.
Publicado: (2018) -
Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink
por: Abtahi, Shahab, et al.
Publicado: (2021) -
The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis
por: Xie, Yanchen, et al.
Publicado: (2017)